Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Bethesda North Marriott Hotel and Conference Center

Sep 20, 2018 7:00 AM - Sep 21, 2018 12:45 PM

5701 Marinelli Road, , North Bethesda, MD 20852 , USA

Advancing the Science of Study Endpoints

Session 9: Selecting COA Endpoints and Analyzing COA Data in Rare Disease - Dealing with Small Sample Sizes and Heterogeneity

Session Chair(s)

Emuella  Flood

Emuella Flood

Director, Patient-Reported Outcomes, AstraZeneca, United States

Rare disease populations are typically small and heterogeneous, and often involve different subtypes, such as specific gene mutation subgroups, further reducing sample sizes. Specific COA-related challenges related to small sample sizes and heterogeneity of rare diseases include the selection and validation of COA measures and analyzing and interpreting the COA data to support treatment benefit. This session will identify the challenges of selecting COA endpoints and analyzing COA data in rare disease populations, including in evaluating psychometric properties of COA instruments. Potential Solutions will be offered, illustrated though case examples. The regulatory perspective on addressing these challenges will also be presented.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Identify the challenges of COA endpoint selection and analysis in rare disease populations and potential solutions, such as the use of RWE and composite endpoints
  • Employ strategies to perform psychometric validation in small, heterogeneous samples
  • Discuss the regulatory perspective on endpoint selection and analysis in rare disease

Speaker(s)

Laura Lee  Johnson, PHD

Laura Lee Johnson, PHD

Director, Division of Biometrics III, Office of Biostatistics, OTS, CDER, FDA, United States

Selecting COA Endpoints and Analyzing COA Data in Rare Disease-Dealing with Small Sample Sizes and Heterogeneity

Linda  Nelsen, MHS

Linda Nelsen, MHS

Senior Director and Head, Oncology Patient-Centered Outcomes, GlaxoSmithKline, United States

Selection and Development of Patient-focused COAs for Rare Disease Clinical Trials

Jeffrey  Palmer

Jeffrey Palmer

Senior Director, Biostatistics, Pfizer Inc, United States

Selecting COA Endpoints and Analyzing COA Data in Rare Disease-Dealing with Small Sample Sizes and Heterogeneity

R.J.  Wirth, PHD

R.J. Wirth, PHD

CEO, VPG Health, United States

Psychometric Evaluation with Small Samples

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.